Prospector Partners LLC Has $11.57 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Prospector Partners LLC raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 20.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 160,491 shares of the medical equipment provider’s stock after acquiring an additional 27,786 shares during the quarter. Prospector Partners LLC owned about 0.07% of Hologic worth $11,570,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HOLX. State Street Corp increased its holdings in shares of Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Hologic by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock valued at $412,159,000 after buying an additional 144,838 shares during the period. Victory Capital Management Inc. raised its position in shares of Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after acquiring an additional 24,358 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Hologic by 3.0% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock valued at $322,272,000 after acquiring an additional 129,035 shares during the period. Finally, Boston Partners boosted its holdings in Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on HOLX. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Wolfe Research initiated coverage on shares of Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. Morgan Stanley dropped their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Jefferies Financial Group started coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Shares of HOLX opened at $60.86 on Friday. The firm’s 50 day moving average price is $64.30 and its two-hundred day moving average price is $72.59. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a twelve month low of $59.06 and a twelve month high of $84.67. The firm has a market cap of $13.66 billion, a P/E ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.